NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript

12:00am, Sunday, 10'th Nov 2019

Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT

03:57am, Saturday, 09'th Nov 2019

Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call

Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results

12:00pm, Wednesday, 06'th Nov 2019

- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...

Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate

12:00am, Wednesday, 06'th Nov 2019

Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60%

02:10pm, Monday, 04'th Nov 2019

This week we saw the Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) share price climb by 22%. But that isn't much...

58 Biggest Movers From Friday

12:00am, Monday, 04'th Nov 2019

50 Stocks Moving In Friday's Mid-Day Session

12:00am, Friday, 01'st Nov 2019

Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019

12:30pm, Thursday, 31'st Oct 2019

TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a li

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by